Spark Therapeutics, Inc. (ONCE) CEO Jeffrey D. Marrazzo Sells 20,000 Shares

Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now directly owns 250,000 shares in the company, valued at approximately $17,885,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Spark Therapeutics, Inc. (ONCE) opened at $72.65 on Tuesday. Spark Therapeutics, Inc. has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s revenue was up 45.8% on a year-over-year basis. During the same period in the prior year, the business earned ($1.07) earnings per share. analysts expect that Spark Therapeutics, Inc. will post -7.62 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.truebluetribune.com/2017/11/14/spark-therapeutics-inc-once-ceo-jeffrey-d-marrazzo-sells-20000-shares.html.

A number of hedge funds have recently made changes to their positions in ONCE. BlackRock Inc. grew its holdings in Spark Therapeutics by 11,332.0% during the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after acquiring an additional 1,824,117 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Spark Therapeutics during the 2nd quarter worth $30,848,000. Jennison Associates LLC acquired a new position in Spark Therapeutics during the 3rd quarter worth $27,239,000. JPMorgan Chase & Co. grew its holdings in Spark Therapeutics by 15.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Finally, Sectoral Asset Management Inc acquired a new position in Spark Therapeutics during the 2nd quarter worth $6,052,000. 77.94% of the stock is owned by institutional investors.

Several research firms have recently issued reports on ONCE. Cantor Fitzgerald dropped their price objective on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a research report on Friday, October 13th. Cowen and Company reissued a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Barclays PLC increased their price objective on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Chardan Capital reissued a “buy” rating and issued a $100.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 13th. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the stock. Spark Therapeutics presently has a consensus rating of “Buy” and an average price target of $90.36.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply